Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: Results from the CORAL-2 study

Cristina Tural, Ricard Solà, Núria Pérez Àlvarez, José Moltó, Matilde Sánchez, Ana Moreno Zamora, Arelly Ornelas, Montserrat Laguno, Juan González, Miguel Ángel Von Wichmann, Maria Jesús Téllez, Roger Paredes, Bonaventura Clotet

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Background: It is uncertain whether a 4-week induction period of pegylated interferon and ribavirin increases early virological response (EVR) in HIV-HCV-coinfected patients. Methods: HIV and HCV genotype 1- and 4-coinfected subjects were randomized to receive pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily and epoetin-β for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin (WBR) dosage for 8 weeks (induction arm [IA]), or pegylated interferon-α2a plus WBR for 12 weeks (standard therapy arm [SA]). HCV RNA was determined at weeks 0, 1, 2, 3, 4, 8 and 12. Ribavirin plasma trough concentrations were determined at weeks 4 (RBV-C4) and 12 (RBV-C12). Results: A total of 67 patients were included; 33 in the SA and 34 in the IA. Overall, 25% received nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens. More patients achieved an HCV RNA decrease ≥1 log10 at week 4 in the IA than in the SA (62% versus 38%; P=0.017), but EVR rates were similar in the two groups (74% versus 59% in the IA and SA, respectively; P=0.15). Independent predictors of faster HCV RNA decrease at 12 weeks were higher RBV-C4 and younger age. RBV-C4 were higher in patients allocated in the IA and in those receiving NRTIs (P=0.039). Conclusions: A 4-week induction with pegylated interferon-α2a plus ribavirin was associated with a greater decrease in HCV RNA at week 4; however, this did not translate into higher EVR rates. Higher RBV doses and avoidance of NRTI-sparing antiretroviral regimens might improve HCV treatment efficacy. ©2011 International Medical Press.
Original languageEnglish
Pages (from-to)833-841
JournalAntiviral Therapy
Volume16
Issue number6
DOIs
Publication statusPublished - 23 Sep 2011

Fingerprint

Dive into the research topics of 'Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: Results from the CORAL-2 study'. Together they form a unique fingerprint.

Cite this